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Summary
Complex interplay between T helper (Th) cells and macrophages contributes to the formation and progression of athero-
sclerotic plaques. While Th1 cytokines promote inflammatory activation of lesion macrophages, Th2 cytokines attenuate
macrophage-mediated inflammation and enhance their repair functions. In spite of its biologic importance, the biochemical
and molecular basis of how Th2 cytokines promote maturation of anti-inflammatory macrophages is not understood. We
show here that in response to interleukin-4 (IL-4), signal transducer and activator of transcription 6 (STAT6) and PPARg-
coactivator-1b (PGC-1b) induce macrophage programs for fatty acid oxidation and mitochondrial biogenesis. Transgenic
expression of PGC-1b primes macrophages for alternative activation and strongly inhibits proinflammatory cytokine
production, whereas inhibition of oxidative metabolism or RNAi-mediated knockdown of PGC-1b attenuates this immune
response. These data elucidate a molecular pathway that directly links mitochondrial oxidative metabolism to the anti-
inflammatory program of macrophage activation, suggesting a potential role for metabolic therapies in treating atherogenic
inflammation.Introduction
Atherosclerosis is the primary cause of mortality from coronary
artery disease in the Western societies (Hansson, 2005). Al-
though initially considered to be a passive disorder arising
from deposition of lipids in the vessel wall, atherogenesis is
now recognized as an active inflammatory condition, involving
complex interactions between the endothelium, smooth muscle
cells, and the immune system (Glass and Witztum, 2001; Hans-
son, 2005). In this contemporary view, endothelial dysfunction,
resulting from hypercholesterolemia, hypertension, diabetes,
or smoking, initiates a proinflammatory reaction in the vessel
wall, resulting in recruitment of lymphocytes and macrophages.
If persistent, this influx of leukocytes promotes a chronic inflam-
matory state, eventually leading to clinically significant stenosis
or thrombosis.
Development and progression of atherosclerotic plaques is
dictated by a balance between pro- and anti-inflammatory
factors (Binder et al., 2002; Hansson, 2005). Interestingly,
macrophages recruited to the injured endothelium orchestrate
both the initiation and resolution of atherogenic inflammation
(Goerdt and Orfanos, 1999; Gordon, 2003). For instance, early
in atherogenesis, Th1 cytokine interferon g (IFNg) and the invad-
ing lipoproteins promote classical activation of lesional macro-
phages, resulting in the secretion of proinflammatory cytokines,
metalloproteinases, and hydrolases. This proinflammatory
program serves to protect the host by scavenging, degrading,
and clearing offending lipoproteins. However, if excessive and
unabated, this inflammatory response becomes detrimentalCELL METABOLISM 4, 13–24, JULY 2006 ª2006 ELSEVIER INC. DOIand retards the healing process (Goerdt and Orfanos, 1999).
In this context, recent studies suggest that the Th2 cytokines
interleukin-4 (IL-4) and IL-13 activate STAT6 to promote matu-
ration of alternatively activated macrophages to counteract
excessive inflammation and enhance repair of tissues (Gordon,
2003; Herbert et al., 2004; Rauh et al., 2005; Stout and Suttles,
2004). These macrophages can be distinguished by their ex-
pression of arginase I, which metabolizes arginine to proline,
leading to collagen production and fibrosis (Gordon, 2003;
Mosser, 2003). Since the two arginine-metabolizing enzymes,
inducible nitric oxide synthase (iNOS) and arginase I, are recip-
rocally regulated by Th1- and Th2-type cytokines, respectively,
the magnitude and duration of macrophage respiratory burst is
directly controlled by the Th1/Th2 balance (Rauh et al., 2005;
Rutschman et al., 2001). In support of this notion, atheroscle-
rotic lesions in IFNg R/apoE double-knockout mice are mark-
edly smaller and exhibit a substantial increase in their collagen
content (Gupta et al., 1997), indicating that loss of Th1 signaling
polarizes macrophages to the less-inflammatory alternative
state. Furthermore, it has been postulated that the Th2-biasing
effects of statins might account for a significant portion of their
antiatherogenic actions (Arnaud et al., 2005; Schonbeck and
Libby, 2004). However, despite the therapeutic potential of alter-
natively activated macrophages, little is known about the regu-
latory factors and pathways that control their maturation.
The PGC-1 family of transcriptional coactivators provide a
potential molecular link between cellular programs of inflamma-
tion and lipid homeostasis (Lin et al., 2005a). Although initially
identified as master regulators of oxidative metabolism10.1016/j.cmet.2006.05.011 13
A R T I C L E(Puigserver et al., 1998), these coactivator proteins are highly
versatile in their functions. By interacting with tissue-specific
transcription factors, the PGC-1 proteins regulate various cellu-
lar processes, including thermogenesis, muscle fiber type spec-
ification, gluconeogenesis, lipogenesis, and cytokine signaling
(Lin et al., 2002, 2005b; Puigserver et al., 1998, 2001; Yoon
et al., 2001). For instance, the catabolic effects of proinflamma-
tory cytokines are mediated by PGC-1a. In this case, stimulation
of muscle cells by Th1-type cytokines leads to phosphorylation
and activation of PGC-1a, which in turn increases uncoupled
respiration and energy expenditure in myocytes. Given the abil-
ity of PGC-1 proteins to transcriptionally integrate cytokine and
lipid signals, we investigated whether PGC-1 might also regulate
programs of macrophage activation. We show here that stimu-
lation of macrophages with IL-4 robustly induces PGC-1b and
upregulates the genetic program for oxidative metabolism. No-
tably, PGC-1b coactivates the transcriptional functions of
STAT6 to metabolically polarize macrophages to the alternative
state, thereby attenuating their inflammatory burst. Taken to-
gether, these findings delineate a novel mechanism by which
metabolic regulators can control macrophage activation,
thereby providing an additional therapeutic strategy with which
to combat atherogenic inflammation.
Results
Induction of oxidative metabolism and PGC-1b
during alternative macrophage activation
To examine the crosstalk between immune programs of macro-
phage activation and lipid homeostasis, we used cDNA micro-
arrays to interrogate gene expression patterns of classically
(highly inflammatory) and alternatively (less inflammatory) acti-
vated macrophages. Clustering analysis revealed that genes
involved in fatty acid oxidation were strongly induced in alterna-
tively, but not classically, activated macrophages (Figure 1A).
Notably, expression of enzymes important in mitochondrial ox-
idation of fatty acids, including acyl-CoA dehydrogenases and
enoyl CoA hydratases, was significantly enhanced by IL-4.
Northern blot analyses further revealed that mRNAs encoding
proteins necessary for fatty acid uptake (LPL, lipoprotein lipase;
PPARg, peroxisome proliferator activated receptor-g), transport
(CD36, fatty acid transporter; CPT1, carnitine palmitoyltransfer-
ase I), and oxidation (MCAD, medium chain acyl-CoA dehydro-
genase; LCAD, long chain acyl-CoA dehydrogenase) were
concurrently induced in the less-inflammatory alternatively acti-
vated macrophages (Figure 1B and Figure S1A in the Supple-
mental Data available with this article online), thereby providing
independent verification of the microarray data. Interestingly, in-
duction of the macrophage oxidative program was accompa-
nied by an increase in the expression of PGC-1b mRNA (Fig-
ure 1B). Immunoblot analyses further verified that stimulation
of bone marrow-derived or thioglycolate-elicited macrophages
with IL-4 robustly induced the expression of PGC-1b protein
(Figure 1C). Since these changes in gene expression were
absent in STAT6-deficient macrophages, they are likely a direct
effect of IL-4. Lastly, a reciprocal pattern of regulation was
observed between alternatively and classically activated macro-
phages for genes involved in b-oxidation of fatty acids and in-
flammation (Figures 1A and S1A), suggesting that oxidative me-
tabolism might be intrinsically linked to the less-inflammatory
alternative state.14To determine the significance of increased expression of
b-oxidation genes in IL-4-stimulated macrophages, we mea-
sured the rates of glucose uptake, fatty acid uptake, and fatty
acid oxidation in macrophages stimulated to undergo classical
or alternative activation. As expected, classical activation of
macrophages by IFNg and lipopolysaccharide (LPS) strongly
induced uptake of glucose byw450% (Figure 1D) and concom-
itantly suppressed the rates of fatty acid uptake and oxidation
by w40% (Figures 1E and 1F). In contrast, uptake of both glu-
cose and fatty acids was increased in alternatively activated
macrophages by w200% (Figures 1D and 1E). Importantly,
stimulation of macrophages with IL-4 increased the rate of
b-oxidation by w200% (Figure 1F), indicating that a switch in
nutrient utilization accompanies alternative macrophage activa-
tion. Together, these data clearly show that while classically
activated macrophages preferentially utilize glucose, the alter-
native program of macrophage activation switches over to fatty
acid oxidation for energy homeostasis.
Oxidative metabolism is required for maturation
of anti-inflammatory macrophages
Induction of oxidative metabolism in alternatively activated
macrophages suggested that it might be integrally linked to
the expression of the anti-inflammatory alternative phenotype.
To investigate this relationship, we pharmacologically inhibited
mitochondrial respiration in macrophages stimulated to un-
dergo alternative activation. Inhibition of fatty acid oxidation
by etomoxir (Djouadi et al., 1999) dramatically decreased the
induction of arginase activity (Figure 2A), a hallmark of anti-
inflammatory alternatively activated macrophages (Goerdt and
Orfanos, 1999; Gordon, 2003; Mosser, 2003). Similarly, oligo-
mycin and FCCP, which inhibit oxidative phosphorylation and
uncouple mitochondrial respiration (Wu et al., 1999), re-
spectively, strongly reduced arginase activity, as detected by
conversion of arginine to urea (Figure 2A) (Rutschman et al.,
2001). Consistent with this decrease in enzymatic activity,
mRNAs encoding arginase I and two endocytic receptors, dec-
tin-1 and mannose receptor, showed an absolute dependence
on oxidative metabolism for their induction by IL-4 (Figure 2B)
(Munder et al., 1999; Stein et al., 1992; Willment et al., 2003).
Flow cytometric analyses of these and other alternative acti-
vation makers (Gordon, 2003; Loke and Allison, 2003) further
supported this conclusion (Figures S2A–S2C). Moreover, since
alternatively activated macrophages are known to counteract
excessive production of proinflammatory cytokines (Goerdt
and Orfanos, 1999; Gordon, 2003; Herbert et al., 2004), we ex-
amined whether inhibition of mitochondrial respiration could
also abrogate this response. Indeed, as assayed by the secre-
tion of IL-6, tumor necrosis factor a (TNF-a), and IL-12, pretreat-
ment of macrophages with mitochondrial inhibitors completely
abolished the anti-inflammatory effects of IL-4 (Figures 2C–
2E). In contrast, inhibition of mitochondrial respiration did not
have any significant effect on inflammatory activation of macro-
phages by IFNg and lipopolysaccharide (Figures 2C–2E). It is
important to note that incubation of macrophages with meta-
bolic inhibitors did not significantly alter the cellular ATP, cal-
cium, STAT6, or PGC-1b levels (Figures 2F, S2D, and S2E). In
aggregate, these results provide evidence for direct involvement
of mitochondrial oxidative metabolism, potentially independent
of STAT6 and PGC-1b, in full expression of the anti-inflamma-
tory alternative phenotype.CELL METABOLISM : JULY 2006
Metabolic control of macrophage activationFigure 1. Induction of oxidative metabolism and PGC-1b during alternative macrophage activation
A) Cluster analysis of macrophage gene expression during alternative and classical activation. Note the reciprocal pattern of expression for inflammatory genes with those
involved in fatty acid metabolism.
B) IL-4 induces genes required for fatty acid metabolism in a STAT6-dependent manner. Average fold induction relative to untreated wild-type sample is indicated.
C) Induction of endogenous PGC-1b protein by IL-4 in a STAT6-dependent manner. 75 mg of total cellular lysates from wild-type or STAT6 null macrophages were sub-
jected to immunoblot analysis with a PGC-1b antibody. Top panel: bone marrow-derived macrophages (BMDM); bottom panel: thioglycolate (TG)-elicited macrophages.
D–F) Alternative activation increases reliance on fatty acid metabolism, as measured by uptake of glucose (C), uptake of fatty acids (D), and b-oxidation of fatty acids (E).
*p < 0.05, **p < 0.005.STAT6 transcriptionally regulates oxidative
metabolism in macrophages
Although IL-4 exerts a majority of its immunological effects on
macrophages via STAT6 proteins (Ihle, 2001; Takeda and Akira,
2000; Wurster et al., 2000), the role of this transcription factor in
orchestrating the macrophage metabolic response has not been
investigated to date. Gene expression analysis of macrophages
revealed that IL-4 failed to upregulate key metabolic genes, in-
cluding CD36, LPL, MCAD, LCAD, and PGC-1b, in STAT6 null
macrophages (Figures 1B and 1C). To investigate whether these
metabolic genes might be targets for transcriptional regulation
by STAT6 homodimers, we identified a potential STAT6 re-
sponse element (STAT6RE) in the proximal 0.5kb of the MCAD
promoter. Gel mobility shift assays with nuclear extracts fromCELL METABOLISM : JULY 2006wild-type and STAT6 null macrophages confirmed binding to
the MCAD-STAT6RE in an IL-4 dependent manner (Figure 3A).
Moreover, competition with excess unlabeled probe and anti-
body supershift assays verified the specificity of STAT6 binding
and its presence in the IL-4-induced retarded complexes, re-
spectively (Figure 3A) (Ohmori et al., 1996). To examine whether
the identified MCAD-STAT6RE could function in vivo, transient
transfection experiments were performed with a reporter con-
struct containing the 0.5 kb of the MCAD promoter. Treatment
with IL-4 led to robust activation of the MCAD promoter in tran-
siently transfected RAW264.7 cells (Figure 3B). Moreover, muta-
tion of STAT6 binding site completely abolished the inductive
effects of IL-4 on this promoter. Interestingly, consistent with in-
creased basal expression of MCAD mRNA in STAT6-deficient15
A R T I C L EFigure 2. Requirement for oxidative metabolism in maturation of anti-inflammatory alternatively activated macrophages
A) Inhibition or uncoupling of mitochondrial respiration prevents induction of arginase activity by IL-4.
B) Mitochondrial respiration is required for expression of the alternative phenotype, as quantified by induction of various mRNAs.
C–E) Mitochondrial inhibitors diminish the anti-inflammatory effects of IL-4. Control and treated macrophages were costimulated with IFNg (1 u/ml) / LPS (2.5 ng/ml) in the
presence or absence of IL-4 (5 ng/ml). ELISAs were used to quantify the secreted (C) IL-6, (D) IL-12p40 and (E) TNF-a by macrophages. Eto, etomoxir; Oligo, oligomycin.
**p < 0.005.
F) IL-4 signaling is intact in macrophages treated with metabolic inhibitors, as measured by induction of PGC-1b and phosphorylation of STAT6.macrophages (Figure 1B), mutation of STAT6RE increased
basal activity of the MCAD promoter. These findings imply that
in addition to transcriptionally activating gene expression,
STAT6 might also have an important role in target gene repres-
sion (Schroder et al., 2002).
To elucidate the regulatory role of STAT6 in oxidative metab-
olism, we measured the uptake and utilization of fatty acids in
wild-type and STAT6 null macrophages. Consistent with the im-
paired induction of mRNAs for fatty acid catabolism, stimulation
with IL-4 did not significantly change fatty acid uptake or oxida-
tion in STAT6 null macrophages (Figures 3C and 3D). However,
the basal rate for fatty acid oxidation was higher in STAT6 null
macrophages, potentially reflecting a compensatory response,
as evidenced by increased expression of MCAD mRNA in these
cells (Figures 3C and 3D). Balanced, and often reciprocal,16metabolism of glucose and fatty acids supports cellular energy
homeostasis. Since STAT6-deficient macrophages exhibit
higher reliance on fatty acid metabolism, we postulated that
this might represent a compensatory response to decreased
glycolytic flux. Indeed, as shown in Figure 3E, both basal and
IL-4-stimulated rates of glucose uptake were reduced by
w45% and w70%, respectively, in STAT6 null macrophages
(Figure 3E). Together, these results demonstrate that STAT6 is
required for both basal and IL-4-dependent changes in glucose
and fatty acid homeostasis.
The ability of STAT6 to regulate macrophage oxidative metab-
olism suggested that this transcription factor might also play an
important role in mitochondrial biogenesis. Alternative, but not
classical, activation of wild-type macrophages led to a dramatic
increase in cellular mitochondrial mass, as quantified by stainingCELL METABOLISM : JULY 2006
Metabolic control of macrophage activationFigure 3. STAT6 regulates oxidative metabolism in alternatively activated macrophages
A) Identification of STAT6 binding sites in MCAD promoter. NRRE, nuclear receptor response element. Gel mobility shift assays were performed with nuclear extracts from
wild-type and STAT6 null macrophages; SS-supershift of STAT6.
B)STAT6 homodimers transactivate the MCAD promoter. Note that mutation of STATRE in the MCAD promoter abolishes IL-4 induction, but raises basal promoter activity.
C–E) Loss of STAT6 affects both basal and IL-4 induced metabolic fluxes in macrophages; (C) fatty acid uptake, (D) fatty acid oxidation, and (E) glucose uptake. *p < 0.05,
**p < 0.005.
F and G) Stimulation with IL-4 fails to increase cellular mitochondrial content in STAT62/2 macrophages, as measured by (F) MitoFluor Green and (G) VDAC1, a-ATPase,
and CytC protein levels. Equivalent loading was confirmed by immunoblotting for b-actin.with MitoFluor Green (Figures 3F and S3A). Strikingly, IL-4 failed
to induce PGC-1b expression (Figures 1B and 1C) and increase
cellular mitochondrial content in STAT6-deficient macrophages
(Figure 3F). As expected from their higher oxidative capacity,
STAT6 null macrophages had more mitochondria and increased
expression of some mitochondrial proteins, including voltage
dependent anion channel 1 (VDAC1) and ATP synthase a
(a-ATPase), in their basal state (Figure 3G). However, the ability
of IL-4 to enhance the expression of all three mitochondrial
proteins, VDAC1, a-ATPase, and cytochrome C (CytC), was
completely abrogated in STAT6 null macrophages (Figure 3G),
indicating that IL-4 is the physiologic trigger that couples mac-
rophage oxidative metabolism to the larger program of immune
activation via STAT6. Lastly, this compensatory increase in
macrophage oxidative metabolism was not accompanied by
any significant changes in the expression of transcription factorsCELL METABOLISM : JULY 2006regulating mitochondrial biogenesis (Figure S3B) or an aberrant
increase in the coactivator protein PGC-1a (data not shown).
Constitutive expression of PGC-1b downregulates
macrophage inflammatory responses
The induction of PGC-1b by IL-4 suggested that this coactivator
might in turn modulate the transcriptional activity of STAT6,
thereby directly participating in the maturation of anti-inflamma-
tory macrophages. To investigate this possibility, we examined
the ability of PGC-1b to coactivate the STAT6-responsive argi-
nase I promoter. As expected, activation of latent STAT6 pro-
teins by IL-4 led tow2-fold increase in the arginase I promoter
activity in transiently transfected RAW264.7 cells (Figure 4A)
(Pauleau et al., 2004). Notably, addition of PGC-1b strongly en-
hanced STAT6 activity on the arginase I promoter (w8-fold over
basal levels, Figure 4A). Mutation of the STAT6 binding site,17
A R T I C L EFigure 4. PGC-1b enhances maturation of anti-inflammatory alternatively activated macrophages
A)Coactivation of STAT6 by PGC-1b on arginase I promoter. RAW264.7 cells were transiently transfected with wild-type arginase I promoter (Arg I-luc) or STAT6RE mutant
(Arg-DSTAT6-luc) reporter constructs, in the presence or absence of PGC-1b.
B) Coimmunoprecipitation of PGC-1b and STAT6.
C) Real-time ChIP analysis for the arginase promoter. Both STAT6 and PGC-1b are recruited to the arginase promoter after stimulation of macrophages with IL-4.
D) PGC-1b enhances arginase activity during alternative macrophage activation.
E and F) Expression of PGC-1b attenuates inflammatory activation of macrophages. ELISA measurements for secreted IL-6 (E) and IL-12 p40 subunit (F). *p < 0.02,
**p < 0.005.which is located in the enhancer region of arginase I promoter
(Pauleau et al., 2004), completely abolished the ability of
STAT6 and PGC-1b to activate this promoter, indicating that
PGC-1bmight directly interact with STAT6 on the arginase I pro-
moter. Indeed, in coimmunoprecipitation assays, Flag-PGC-1b
(f-PGC-1b) existed in a soluble complex with and efficiently pre-
cipitated STAT6 (Figure 4B). To determine whether PGC-1b is
recruited to the STAT6RE in the distal enhancer of arginase I,
we performed quantitative chromatin immunoprecipitation
(ChIP) assays. As shown in Figure 4C, stimulation of macro-
phages with IL-4 led to increased corecruitment of STAT6 and
PGC-1b to the arginase I enhancer, indicating that transcription-
ally active STAT6 can efficiently recruit PGC-1b in close proxim-
ity to its binding site.
A unique feature of PGC-1 coactivators is their ability to cou-
ple mitochondrial biogenesis to biological processes that are18associated with increased oxidative metabolism (Lin et al.,
2002, 2005a). To investigate whether constitutive expression
of PGC-1b could similarly polarize macrophages toward the
more oxidative alternative state, we retrovirally introduced
f-PGC-1b into wild-type macrophages (Figure S4A). As
expected, fatty acid oxidation rates were w160% higher in
f-PGC-1b expressing cells, consistent with the known metabolic
effects of this coactivator (Figure S4B). Strikingly, constitutive
expression of f-PGC-1b increased IL-4 induced urea production
via arginase I by w800%–900% (Figure 4D), suggesting that
PGC-1b can indeed potentiate macrophage activation along
the less-inflammatory alternative axis. Notably, this enhance-
ment of arginase I activity by f-PGC-1b was independent of
changes in total or phosphorylated STAT6 protein levels (Fig-
ure S4C). To further examine whether priming by PGC-1b might
attenuate inflammatory activation of macrophages, control andCELL METABOLISM : JULY 2006
Metabolic control of macrophage activationFigure 5. Requirement for PGC-1b in alternative macrophage activation
A) Knockdown of endogenous PGC-1b protein by retroviral expression of RNAi. Wild-type macrophages were stably infected with retroviral vectors expressing shRNAs
against GFP or PGC-1b. Whole-cell lysates were analyzed by immunoblotting for endogenous PGC-1b.
B) Requirement for PGC-1b in IL-4-stimulated increase in b-oxidation of fatty acids.
C) Arginase activity in control and PGC-1b knockdown macrophages. Macrophages were stimulated IL-4 (5 ng/ml) for 24 hr prior to assaying for urea production.
DandE)Role of PGC-1b in inhibition of macrophage inflammatory activation. Macrophages were stimulated by LPS (1 ng/ml) in the presence of IL-4 (2 ng/ml), and secreted
cytokine culture supernatants were quantified by ELISAs. Representative data are shown above (n = 3). *p < 0.05; **p < 0.004.f-PGC-1b expressing cells were challenged with LPS, and cyto-
kine secretion was quantified by ELISAs. f-PGC-1b expression
strongly reduced the secretion of inflammatory cytokines, IL-6
and IL-12, in LPS-challenged macrophages (Figures 4E and
4F). Moreover, cell surface expression of dectin-1, a marker of
alternatively activated macrophages, was robustly induced by
PGC-1b (Figure S4D). Taken together, these results suggest
that cooperation between the IL-4 signaling pathway and
PGC-1b is critical in polarizing macrophages to the more oxida-
tive, less-inflammatory alternative state.
PGC-1b knockdown impairs alternative
macrophage activation
The induction of PGC-1b by IL-4 suggested that PGC-1b might
be required for transcriptional activation of STAT6 functions in
macrophages. To test this possibility, we used shRNAs that
have previously been shown to be highly specific and effective
in knocking down PGC-1b protein expression (Lin et al.,
2005b). As shown in Figure 5A, retrovirally mediated stable
expression of two distinct shRNAs led to greater than 80%
knockdown of endogenous PGC-1b in macrophages. As ex-
pected, the ability of IL-4 to promote b-oxidation of fatty acids
was reduced by 35%–52% in the PGC-1b knockdown cellsCELL METABOLISM : JULY 2006(Figure 5B). Demonstrating a key role of PGC-1b in the matura-
tion of less-inflammatory alternatively activated macrophages,
knockdown of PGC-1b by RNAi reduced arginase activity
by 61%–72% (Figure 5C). Furthermore, the anti-inflammatory
actions of the Th2 cytokine IL-4 were greatly diminished in
PGC-1b knockdown macrophages, as evidenced by the inabil-
ity of IL-4 to completely suppress the release of IL-6 or IL-12 p40
subunit (Figures 5D and 5E). It is important to note that, in the
absence of IL-4 stimulation, there was no significant difference
between the inflammatory activation of control and PGC-1b
knockdown macrophages (Figures S5A and S5B), indicating ex-
quisite specificity for the anti-inflammatory functions of PGC-1b
to the alternative state. Finally, in contrast to the potent inhibition
of alternative macrophage activation by inhibitors of oxidative
metabolism, macrophages with PGC-1b knockdown still re-
tained some capacity to undergo alternative activation, perhaps
reflecting the residual activity of PGC-1b protein or IL-4 induced
increase in oxidative metabolism.
Decreased Th1-type macrophage inflammation
in PGC-1b transgenic mice
To address whether PGC-1b can prime macrophages toward
the less-inflammatory alternative state in vivo, we generated19
A R T I C L EFigure 6. Transgenic expression of PGC-1b potentiates alternative activation and attenuates macrophage-mediated inflammation in vivo
A) hCD68 promoter directs PGC-1b transgene expression to macrophages. Lysates from wild-type or Mac-PGC-1b macrophages were analyzed by immunoblotting for
PGC-1b (middle panel). PGC-1b is expressed at a level equivalent to that found in IL-4-stimulated wild-type macrophages (right panel).
B) PGC-1b potentiates expression of arginase I mRNA, as assessed by Northern blots.
C) Fold increase in arginase activity in macrophages from wild-type and Mac-PGC-1b mice after stimulation with IL-4 (2 ng/ml) for 24 hr.
D and E) Transgenic expression of PGC-1b attenuates macrophage inflammatory burst. BMDM from wild-type and PGC-1b transgenic mice were stimulated with IFNg
(1 u/ml) for 20 hr prior to challenge with LPS (0.5 ng/ml). Cytokine secretion was assayed 6 hr later by ELISAs. *p < 0.04.transgenic mice expressing f-PGC-1b under the control of hu-
man CD68 promoter, a promoter that preferentially directs
transgene expression to macrophages (Figure 6A) (Gough
et al., 2001; Lang et al., 2002). Two positive founder lines, which
gave germline transmission, were expanded to establish the
Mac-PGC-1b transgenic colonies. Importantly, macrophages
derived from the transgenic animals showed robust expression
of the PGC-1b protein (Figure 6A). Consistent with the tissue-
specificity of the CD68 promoter, we failed to detect expression
of Flag-PGC-1b in skeletal muscle or adipose tissue of lean mice
(data not shown). Moreover, analysis of macrophage proteins
revealed that founder #1 expresses PGC-1b to the same level
as that seen in IL-4-stimulated wild-type macrophages (Fig-
ure 6A). To examine whether transgenic expression of PGC-1b
potentiated the IL-4 driven macrophage program of alternative
activation, we measured arginase I mRNA and activity levels in
BMDM after IL-4 stimulation. As shown in Figures 6B and 6C,
expression of arginase I mRNA and induction of arginase activity
was dramatically higher in macrophages derived from PGC-1b
transgenic mice. In addition to biasing arginine metabolism
toward the less-inflammatory state, increased expression of
PGC-1b protein led to the attenuation of macrophage-mediated
inflammation, as evidenced by decreased secretion of IL-6 and
IL-12p40 in the culture supernatants (Figures 6D and 6E). In20aggregate, these results demonstrate that PGC-1b can potenti-
ate the alternative program of macrophage activation in vivo,
and that direct coactivation of STAT6 by PGC-1b likely accounts
for a significant portion of this phenotypic switching in macro-
phage immune responses.
Discussion
Recent studies have shown a key role for glycolytic pathways
controlled by hypoxia inducible factor-1a (HIF-1a) in promoting
the effector responses of classically activated macrophages
(Cramer et al., 2003). However, the metabolic and transcrip-
tional bases for maturation of anti-inflammatory alternatively
activated macrophages have remained largely unknown. The
data presented here demonstrates that alternative activation
of macrophages by IL-4 induces cellular pathways for fatty
acid oxidation and mitochondrial biogenesis. In addition to
directly regulating genes important in b-oxidation of fatty acids,
STAT6, which mediates the transcriptional responses of IL-4, is
also required for induction of the coactivator protein PGC-1b. In-
terestingly, a feedforward loop, in which PGC-1b is induced by
and coactivates STAT6, amplifies and sustains the metabolic,
biogenic and anti-inflammatory programs of alternatively acti-
vated macrophages. Lastly, the ability of PGC-1b to potentiateCELL METABOLISM : JULY 2006
Metabolic control of macrophage activationthe macrophage program of alternative activation provides
a unique example of how immune responses can be transcrip-
tionally directed by metabolic coactivators.
Oxidative metabolism fuels alternative
macrophage activation
Four independent lines of evidence support the importance of
oxidative metabolism in priming and elaboration of the less-
inflammatory alternative macrophage phenotype. First, stimula-
tion of macrophages with IL-4 robustly induces the entire pro-
gram for fatty acid metabolism, including uptake and oxidation
of fatty acids, and mitochondrial biogenesis. Second, pharma-
cologic inhibition of oxidative metabolism potently suppresses
the effector functions of alternatively, but not classically, acti-
vated macrophages. Third, STAT6, the transcriptional regulator
of Th2 responses in lymphocytes and macrophages, is the prin-
cipal factor that coordinates the macrophage metabolic pro-
grams in response to IL-4. And finally, transgenic expression
of the metabolic coactivator protein PGC-1b potentiates alter-
native activation, whereas its knockdown by RNAi impairs
both the metabolic and anti-inflammatory functions of alterna-
tively activated macrophages.
Although our results provide unequivocal proof for the re-
quirement of STAT6 in mediating the metabolic response of
the Th2 cytokine IL-4, STAT6-deficient macrophages exhibit a
paradoxical increase in oxidative metabolism. For instance,
basal rates of fatty acid uptake and oxidation are higher in
STAT6 null macrophages (Figures 3C and 3D), perhaps reflect-
ing altered energy homeostasis in these cells. Consistent with
this notion, glucose uptake was dramatically reduced in
STAT6 null macrophages (Figure 3E). Since altered metabolism
of glucose is likely to impact cellular energy homeostasis, we
postulated that compensatory activation of the energy-sensing
AMP-activated protein kinase (AMPK) pathway or induction of
the coactivator protein PGC-1a might be the driving force for in-
creased reliance on b-oxidation of fatty acids (Lin et al., 2005a;
Ruderman et al., 2003). However, despite repeated attempts,
we failed to detect any significant differences between wild-
type and STAT6 null macrophages in the expression or phos-
phorylation of AMPK, and its substrate the acetyl-CoA carb-
oxylase (ACC) (data not shown). Moreover, expression of
PGC-1a mRNA was undetectable by quantitative RT-PCR in
both wild-type and STAT6 null macrophages under various
stimulatory conditions (data not shown), making it unlikely that
these pathways are responsible for the observed metabolic
differences between these macrophages. An alternative expla-
nation might be that, in the absence of IL-4, STAT6 represses
a subset of its target genes, including those involved in b-oxida-
tion. Congruent with this idea, the deletion of STAT6 binding site
in the MCAD promoter or a genetic deficiency of STAT6 protein
in macrophages leads to activation of the MCAD promoter, as
reflected in higher basal promoter activity and expression of
MCAD mRNA (Figures 3B and 1B). Interestingly, similar findings
were reported by Schroder et. al. in activated B cells (Schroder
et al., 2002). In their study, greater than 50% of the differentially
expressed genes were derepressed in STAT6 null cells, implying
that STAT6 directly or indirectly represses a subset of its target
genes. More detailed studies will be required to delineate the ac-
tivation and repression functions of STAT6 in glucose and fatty
acid homeostasis.CELL METABOLISM : JULY 2006Our work raises an intriguing question as to why oxidative me-
tabolism is required for expression of the biologic program
driven by IL-4. One possibility is that metabolic skewing of mac-
rophages, toward glycolytic or oxidative metabolism, is neces-
sary for performance of their critical functions in host defense.
For example, the Th1-type cytokine, IFNg, primes macrophages
to increase production of proinflammatory cytokines, reactive
oxygen species and nitric oxide for safe clearance of intracellu-
lar pathogens (Gordon, 2003; Stout and Suttles, 2004). Energy
required for this respiratory burst is rapidly provided by glyco-
lytic pathways, which are transcriptionally controlled by hypoxia
inducible transcription factor-1a (HIF-1a) (Cramer et al., 2003).
Pharmacological inhibition of glycolysis or genetic deletion of
HIF-1a in myeloid cells greatly reduces cellular ATP content
and has the functional consequence of diminishing their antimi-
crobial activity (Cramer et al., 2003; Peyssonnaux et al., 2005). In
contrast, the Th2-type cytokines IL-4 and IL-13 promote alter-
native macrophage activation to provide a defense against ex-
tracellular parasites (Goerdt and Orfanos, 1999; Gordon, 2003;
Stout and Suttles, 2004). In this case, STAT6 controls the ge-
netic program for long-term macrophage activation (Takeda
and Akira, 2000; Wurster et al., 2000). By increasing the secre-
tion of chitinases, chemokines, and collagen, these alternatively
activated macrophages neutralize the invading parasites, recruit
eosinophils, and promote granuloma formation (Gordon, 2003).
This macrophage secretory program is energetically demand-
ing, both in terms of its intensity and duration. Since oxidative
metabolism is best suited to meet the bioenergetic demands
for long-term macrophage activation, our data suggest that
IL-4 mediated activation of STAT6 serves to transcriptionally
couple the metabolic pathways to the immune functions per-
formed by these cells (Figure 7).
Integration of macrophage metabolic
and immune functions by PGC-1b
Previous studies and the data presented here indicate a critical
role for STAT6 and oxidative metabolism in promoting matura-
tion of anti-inflammatory alternatively activated macrophages.
However, how these distinct cellular pathways are integrated
into a coherent program of macrophage gene expression has
not been described to date. We report here that the coactivator
Figure 7. Model for regulation of macrophage activation by metabolic regulators
HIF-1a and Th1-type stimuli increase glycolytic metabolism to support proinflam-
matory classical activation of macrophages. In contrast, in response to Th2 cyto-
kine IL-4, STAT6, and PGC-1b enhance oxidative metabolism and promote
expression of the less-inflammatory alternative phenotype.21
A R T I C L Eprotein PGC-1b transcriptionally regulates the development of
alternatively activated macrophages. Several key pieces of
data support this claim. First, in a STAT6-dependent manner,
IL-4 induces the expression of PGC-1b mRNA and protein in
both quiescent and activated macrophages. Second, ectopic
expression of PGC-1b leads to marked changes in macrophage
metabolism and function. Transgenic expression of PGC-1b to
levels equal to those induced by IL-4 increases macrophage ox-
idative metabolism and stimulates expression of proteins char-
acteristic of the less-inflammatory alternative state. This likely
represents a physiologic function of PGC-1b, because knock-
down of PGC-1b by RNAi greatly diminishes these responses.
Taken together, the findings presented here greatly broaden
our mechanistic understanding of how Th2 cytokines attenuate
macrophage-mediated inflammation, and provide another ex-
ample for metabolic integration of cellular processes by a family
member of the PGC-1 coactivator proteins. In a manner analo-
gous to muscle fiber conversion by metabolic regulators (Lin
et al., 2002; Wang et al., 2004), our results suggest a model in
which metabolic pathways and their transcriptional regulators
serve as key nodal points for directing pro- and anti-inflamma-
tory programs of macrophage activation (Figure 7). For instance,
HIF-1a and glycolysis promote proinflammatory activation of
macrophages, whereas oxidative metabolism regulated by
STAT6 and PGC-1b primes macrophages for the less-inflamma-
tory alternative state. In addition, these findings raise the possi-
bility that metabolic priming of macrophages to the less-inflam-
matory alternative state might be a principal mechanism by
which therapies that promote utilization of fatty acids, such as
fibric acids and thiazolidinediones, attenuate macrophage-
mediated inflammation in atherosclerosis (Duval et al., 2002;
Zhang and Chawla, 2004).
Experimental procedures
Cell culture
For bone marrow-derived macrophages (BMDM), wild-type and STAT62/2
bone marrow was isolated from femurs and tibias, and cultured in IMDM sup-
plemented with 10% fetal calf serum and 20% L929 conditioned media. Em-
bryonic stem cell-derived macrophages (ESDM) were cultured as described
previously (Chawla et al., 2001), except with the following modifications.
ES-derived myeloid progenitors were conditionally immortalized with eco-
tropic retroviruses encoding HOXA9-ER, a fusion protein that blocks myeloid
differentiation in an estrogen-dependent manner (Sykes and Kamps, 2001).
Wild-type HOXA9-ER lines were proliferated in the presence of SCF
(25 ng/ml), IL-3 (1.25 ng/ml) and estradiol (1 mM). Macrophage differentiation
was induced by withdrawing estradiol and culturing cells in IMDM supple-
mented with 10% bovine calf serum and 20% L929 conditioned media.
Differentiated macrophages developed over 6–7 days. Proliferating
WT-HOXA9-ER lines were infected with control or f-PGC-1b encoding retro-
viruses, and subjected to selection with puromycin (4 mg/ml). Knockdown
of PGC-1b was accomplished by cloning PGC-1b #1 and #2 shRNAs (Lin
et al., 2005b) into pSIREN-Puro retroviral vector. WT-HOXA9-ER cells were
infected with GFP, PGC-1b #1, or PGC-1b #2 shRNA-expressing retro-
viruses, and selected with puromycin (4 mg/ml). For classical or alternative
macrophage activation, macrophages were stimulated with murine
IFNg (100 u/ml) plus LPS (5 ng/ml) or murine IL-4 (10–20 ng/ml) for 24 hr,
respectively.
Generation of PGC-1b transgenic mice
cDNA fragment encoding Flag-tagged mPGC-1bwas subcloned into a vector
containing the hCD68 promoter (Gough et al., 2001). DNA was excised from
the cloning vector and injected into CBA 3 C57Bl6 mouse oocytes. Trans-
genic offspring were genotyped by PCR using the following primers: TY1:
50-TTCTCGGCTCTGTGAATGACA-30 and 50-CAGCCCTCTCTTGGAAAGGA22GG-30. Founder mice were backcrossed onto C57Bl6 background, and
F1-F3 progeny were used for the macrophage experiments.
Gel mobility shift assays and transient transfections
Gel mobility shift assays were performed with nuclear extracts from wild-type
or STAT62/2 macrophages, and 32P end-labeled oligonucleotides. RAW
264.7 cells were transiently transfected by electroporation using GenePulser
II (BioRad) at 300V, 1000 mF, and subsequently stimulated with IL-4
(10 ng/ml) for 12–20 hr. Luciferase assays were performed with the Dual-
Luciferase reporter assay system (Promega) as per manufacturer’s proto-
cols. The 0.5 kb mouse MCAD promoter fragment was generated by PCR
and cloned into the luciferase reporter construct pGL3-Basic (Promega).
All transfections were done in triplicate and repeated at least three times.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays (ChIPs) were performed as de-
scribed (Pauleau et al., 2004) with the following modifications. 2.5 3 106
RAW cells were plated in 10 cm plates, rested overnight, and stimulated
with 10 ng/ml IL-4. Cells were crosslinked with formaldehyde and processed
for ChIP. Each STAT6 immunoprecipitation was performed with 1 mg M200
anti-STAT6 polyclonal antibody (Santa Cruz Biotechnology) mixed with 1 ml
polyclonal anti-STAT6 antibody supplied by James Ihle (St. Jude Children’s
Research Hospital). PGC-1b immunoprecipitations were performed using
affinity purified rabbit polyclonal antibody. Immunoprecipitates were pro-
cessed as described (Pauleau et al., 2004) and subjected to qPCR analysis
using primers specific for the Arginase I enhancer. Data is expressed as rel-
ative enrichment compared to a mouse genomic DNA standard curve. Each
experiment was performed in duplicate, and repeated three independent
times.
Western blot analysis, ELISAs, and flow cytometry
Western blot analyses were performed using standard procedures with
BMDM. Equivalent amounts of cellular protein were analyzed by immuno-
blotting for cytochrome C (1:1000, BD Pharmingen), VDAC1 (1:2000, Sigma),
a-ATPase (1:1000, Molecular Probes), Flag (1:1000, Sigma), PGC-1b (1:500),
and b-actin (1:5000, Sigma). IRDye 800 conjugated secondary antibodies
(1:30000, Rockland) were used for protein detection on Odyssey Infrared De-
tection System. For ELISAs, cells were plated in 48- or 96-well plates and
stimulated with cytokines or LPS for 6–24 hr. TNF-a, IL-6, and IL-12 secretion
was quantified by ELISA, per manufacturer’s protocols (BD Pharmingen). For
flow cytometry, control and IL-4-stimulated macrophages were incubated
with FITC-conjugated antibodies against mannose receptor, dectin-1 and
PD-L2 prior to analysis on FACs Caliber. For measurement of intracellular
calcium, treated macrophages were resuspended in medium containing
1 mM fluo-4AM (added 1:1 with pluronic, a nonionic detergent) for 45 min
at 37ºC and subsequently analyzed by flow cytometry. All assays were
repeated at least three independent times.
Gene expression analysis
Total RNA was prepared from three independent experimental replicates
using Trizol reagent (Invitrogen) and analyzed by Northern blot analyses
(Chawla et al., 2001). Microarray experiments were performed with 20–
25 mg of total RNA, which was labeled with fluorescent nucleotides and
hybridized to murine cDNA slides. Hybridized slides were interrogated via
an Agilent scanner, data was subjected to background subtraction and nor-
malization, and analyzed with statistical analysis of microarrays software
package.
Protein interaction assays
Physical association of PGC-1b with STAT6 was assessed in coimmunopre-
cipitation assays. 293-T cells were transfected with plasmids encoding
f-PGC-1b and murine STAT6. Twenty-four hours after transfection, cells
were stimulated with hIL-4 (10 ng/ml) for 60 min. PGC-1b containing com-
plexes were immunoprecipitated using the Flag antibody (Sigma), resolved
on a denaturing gel and immunoblotted for STAT6 (1:1000, Santa Cruz).
Metabolic assays
For glucose and fatty acid uptake, macrophages were prestimulated with
Th1 or Th2 cytokines and incubated with 14C-labeled 2-deoxy-glucose or
fatty acid-free BSA conjugated 14C-oleic acid, respectively. Subsequently,CELL METABOLISM : JULY 2006
Metabolic control of macrophage activationcells were extensively washed and lysed, and incorporated radioactivity was
quantified. Fatty acid oxidation assays were performed as described previ-
ously (Muoio et al., 2002). For arginase assays, 5 3 105 macrophages were
plated in a 24-well plate and stimulated with IL-4 for 15 hr. Total cellular
arginase activity was monitored via a colorimetric assay that detects the pro-
duction of urea (Rutschman et al., 2001). Total cell number or protein content
was used for normalization. For studies in which oxidative metabolism was
pharmacologically inhibited or uncoupled, macrophages were pretreated
with etomoxir (50 mM), oligomycin (2 mg/ml) or FCCP (50 nM) for 24 hr prior
to stimulation with IL-4. All assays were performed in duplicate or triplicate
and repeated at least three times.
Statistical analyses and array dataset
All statistical analyses were performed using paired Student’s t test, and
results are expressed as mean 6 SEM. A p value < 0.05 was considered to
be significant. The data discussed in this publication have been deposited
in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo/) and are accessible through GEO Series accession number GSE5003.
Supplemental data
Supplemental data include five figures and can be found with this article on-
line at http://www.cellmetabolism.org/cgi/content/full/4/1/13/DC1/.
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